Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

TUSTIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is also being tested in a Phase II clinical trial in patients with recurrent GBM.

In the ongoing dose confirmation and dosimetry study, patients received a single treatment of Cotara and were evaluated for specificity of drug localization to the tumor, as well as for progression-free survival and overall patient survival. Initial data from the trial show that all of the patients in the first two completed study cohorts have survived longer than the expected six-month median survival time for GBM patients and they confirm Cotara's targeting capabilities, indicating that it delivers more than 300-fold higher radiation levels to the tumor than to normal organs.

"Completion of patient enrollment in this study is a significant regulatory milestone for Cotara, representing an important component of the Cotara clinical development program," said Dr. Robert Garnick, head of regulatory affairs at Peregrine. "With enrollment in this trial now completed, we are turning our attention to expanding the ongoing Cotara Phase II GBM trial to further advance the program. Given the encouraging data seen to date in the Cotara brain cancer trials, we plan to explore available clinical and regulatory options for expediting Cotara development."


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Mylan Inc. (Nasdaq: MYL ) today ... company,s credit ratings, including the "Corporate Family Rating," to ... is stable.  According to Moody,s: "Mylan,s ... in the global generic pharmaceutical industry, its strong geographic ...
... a molecular diagnostics company, announced today the publication of ... which may influence the amount of fetal DNA found ... Kypros Nicolaides, MD, of Harris Birthright Research Centre for ... Kingdom. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) ...
... a metal surface at the scale of atoms and ... computer chips or the reflective silver in optical components ... may seem high-tech and precise, the technique has been ... physics. In a new study, Brown University engineers modeled ...
Cached Biology Technology:Moody's Upgrades Mylan 2Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women 2How ion bombardment reshapes metal surfaces 2How ion bombardment reshapes metal surfaces 3
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... in German . ... they also provide us with a continuous stream of information ... or sit still in a car the world glides ... retinas. Seemingly without effort, our brain calculates self-motion from this ... and a steady gaze during our own movements. Together with ...
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... applauds the US Court of Appeals for the District of ... against the use of public funds for embryonic stem cell ... cell research and the nation,s scientific community. Most importantly, ... suffering from incurable diseases," says Susan L. Solomon, CEO of ...
... a groundbreaking new videojournal to complement the ... & Advanced Surgical Techniques has been ... ( http://www.liebertpub.com ). Videoscopy ( http://www.liebertpub.com/products/product.aspx?pid=390 ) ... of the latest techniques and technologies used ...
... ground to plant trees may be an excellent gateway to ... University of Maryland study, based on work with New York ... in environmental stewardship, the more s/he engages with other types ... Together ", which the researchers released to coincide with Arbor ...
Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2Digging in dirt, Arbor Day planting, may help build citizenship: UMD study 2
... Alsevers solution is an isotonic, balanced salt ... preservative, which permits the storage of whole blood ... usage, an equal volume of blood is collected ... but thoroughly, mixed. The solution is placed in ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
... GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, utilizing many ... GCMS-QP2010 Plus, offers high throughput and ... excellent performance-to-cost ratio. Like the GCMS-QP2010 ... linear velocity for optimum separation, 20 ...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
Biology Products: